



Contact Information:

Dennis Dionne
Saladax Biomedical
610.419.6731 ext 26517
DDionne@Saladax.com

Saladax Biomedical to Present at Leading Life Science Conferences in 2007

Doylestown, PA, March 12, 2007 — Saladax Biomedical, Inc. (SBI) has been selected to present at leading scientific and professional conferences addressing both the oncology and in vitro diagnostic professional communities during the course of 2007.

At the American Society of Clinical Oncology (ASCO) annual meeting in June, Saladax will be presenting a poster on its new Busulfan Analyte Specific Reagents (ASRs) entitled A rapid immunoassay to determine concentrations of busulfan in plasma. The poster demonstrates that Saladax's busulfan immunoassay delivers quality results, while offering the advantages of a smaller sample size, no sample preparation and less labor than other testing methods, enabling effective routine monitoring of busulfan levels in clinical practice.

At the American Association for Clinical Chemistry (AACC) annual Lab Expo in July, two presentations will be made on the Saladax Personalized Chemotherapy Management (PCM) assays in development. In 5-Fluorouracil determination in plasma by automated immunoassay, Saladax reports performance of a unique proprietary immunoassay for determining the concentration of this widely used chemotherapeutic agent on the Olympus AU400 instrument. In Evaluation of a rapid immunoassay for busulfan quantitation in plasma at two laboratories, Dr. Gwen McMillin of ARUP Laboratories reports the comparative results of the Saladax Busulfan ASRs demonstrating excellent correlation with GC-MS or LC-MS/MS and generating results substantially faster, thereby enabling improved patient care.

In September at the 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) in Nice, France, Saladax will present two abstracts: A library of novel monoclonal antibodies for determining levels of busulfan in biological fluid, reporting the first library of monoclonal antibodies able

to selectively quantitate busulfan. Saladax has developed fifty-two monoclonal antibodies for busulfan, some of which were highly selective and sensitive. The second abstract to be presented is 5-Fluorouracil determination in plasma by automated immunoassay, demonstrating the quality of test results of the Saladax 5-FU PCM reagent. Also at the Nice conference, Dr. Martin Fleisher of Memorial Sloan Kettering will present Evaluation of a rapid immunoassay for busulfan quantitation in plasma based upon his evaluation of the Saladax busulfan ASR reagents. Additionally, Saladax is sponsoring an industry workshop on the topic of chemotherapy drug management, with presentations by Dr. Erick Gamelin of the Paul Papin Cancer Center in Angers, France as well as Drs. Fleisher, McMillan, and Salamone.

“We are very gratified with the reception and recognition that our work is receiving in among the life science community as we develop our PCM assays,” said Dr. Salvatore J. Salamone, CEO and co-founder of Saladax. “We are also very pleased that the fruit of our development work will ultimately have a very positive impact on the lives of cancer patients.”

About Saladax

Saladax Biomedical is pioneering the development of novel, rapid, and cost-effective immunoassays that will enable routine blood-level monitoring of anti-cancer drugs to become the standard of care in treating cancer patients. With Personalized Chemotherapy Management (PCM), oncologists will be able to adjust the administered dose based on each patient’s individual drug level, leading to reduced toxicity, improved outcome and lower cancer care costs. Saladax is headquartered at the business incubator of the Ben Franklin Technology Partners (BFTP) of Northeastern Pennsylvania on the campus of Lehigh University in Bethlehem. The 5-FU PCM test will be available to U.S. clinicians later this year through a major reference laboratory.